Method for constructing mouse nerve injury animal model based on poxvirus infection

By nasal infection with VR-1354 vaccinia virus in C57BL/6N mice, a mouse model that can simulate the nerve damage caused by poxvirus was constructed, which solved the problem of lack of nerve damage models in the existing models and achieved poxvirus-related relationships Effective simulation and research of diseases.

CN119032898APending Publication Date: 2024-11-29SHANGHAI PUBLIC HEALTH CLINICAL CENT

Patent Information

Application Number
CN202411469264.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-21
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The existing poxvirus infection models are mainly concentrated in several common poxviruses, involving fewer neural damage models, making it difficult to effectively simulate nerve damage and related pathological changes caused by poxvirus.

Method used

By nasal drops in C57BL/6N mice of 3-12 weeks old, a mouse model that can simulate the nerve damage and related pathological changes caused by poxvirus, resulting in lungs A novel animal model of inflammatory response, blood-brain barrier damage, glial cell activation of olfactory bulbs and reduced olfactory nerves.

Benefits of technology

This model can effectively simulate nerve damage caused by poxvirus, and has significant application value in the research and development of poxvirus-related nerve damage drugs, disease prevention research and pathogenic mechanism research, helping to accelerate the discovery and optimization of new therapies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005094252600000061
    Figure BDA0005094252600000061
  • Figure HDA0005094252610000011
    Figure HDA0005094252610000011
  • Figure HDA0005094252610000012
    Figure HDA0005094252610000012
Patent Text Reader

Abstract

The invention relates to the technical field of biomedicine, and discloses a method for constructing a mouse nerve injury animal model based on poxvirus infection, the model is constructed by infecting a mouse nasal drop with poxvirus, and the model can simulate nerve injury and related pathological changes caused by the poxvirus. The vaccinia virus used in the invention can cause serious infection of mice, cause certain damage to blood-brain barriers at olfactory bulb parts, and cause activation and increase of glial nerve cells of olfactory bulb parts and reduction of olfactory nerve quantity or vitality. In view of high conservative property of the poxvirus, the model has remarkable application value in research in the fields of prevention and treatment of related diseases and related pharmacy. For example, the method can be used for research and development and effectiveness screening and evaluation of candidate therapeutic or prophylactic drugs and vaccines for poxvirus infectious olfactory nerve injury. The model is helpful for accelerating the discovery and optimization of a new therapy and improving the prevention capability of coping with poxvirus infection related nerve injury diseases (encephalopathy) in the future.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of biomedical technology, and more specifically, to a method for constructing a mouse neurological injury animal model based on poxvirus infection. Background Art

[0002] As one of the key means in public health and related pharmaceutical fields, animal models of virus infection are of great significance in the prevention and control of infectious diseases, the development of new drugs and the development of basic medicine. Poxvirus is the largest and most complex type of DNA virus known so far. Poxvirus has a special morphology, and its virus particles are complex pseudo-elliptical or brick-shaped. Poxvirus includes multiple genera, among which the orthopoxvirus genus has the strongest virulence. The known monkeypox virus, smallpox virus, and cowpox virus all belong to the orthopoxvirus genus and can cause serious diseases in humans. For example, smallpox virus has caused epidemics around the world, with symptoms including high fever, general discomfort, headache, and subsequent macules, papules, herpes and pustules. Although smallpox has been declared eradicated, other poxviruses such as monkeypox virus still pose a threat to humans and can cause symptoms similar to smallpox. In addition, poxviruses can also cause a variety of animal diseases, such as cowpox, sheeppox, goatpox, etc.

[0003] Experimental animal models are an indispensable and important tool for research in the biological field. By simulating the physiological state of animals after infection through artificial intervention, it provides a reliable tool for studying the occurrence of diseases, the development of drugs, and the prevention and treatment of diseases. There are many types of experimental animal models, such as genetic models, pharmacological models, immune models, disease models, etc. Most of the existing poxvirus infection models are several common poxviruses, such as Tiantan strain vaccinia virus (VTT), vaccinia virus Listeria strain, monkeypox virus, etc., but models involving and focusing on nerve damage are rare. Summary of the invention

[0004] The purpose of the present invention is to construct a new poxvirus-infected mouse model that can be used for biological experiments by infecting mice with poxvirus, causing obvious pathological symptoms in the mouse lungs, damage to the blood-brain barrier, activation and increase of glial cells in the olfactory bulb, and decrease in the activity or number of olfactory nerves.

[0005] The present invention is implemented by the following technical solutions, and the main technical points involved are as follows:

[0006] In a first aspect, the present application discloses an animal model of neurological damage in mice based on poxvirus infection, wherein the model is constructed by infecting mice with poxvirus by nasal drops, and the model can simulate neurological damage and related pathological changes caused by poxvirus.

[0007] Furthermore, the mice are C57BL / 6N mice aged 3-12 weeks.

[0008] Furthermore, the poxvirus is a vaccinia virus with the catalog number VR-1354 on the ATCC official website.

[0009] Furthermore, the model can cause a significant inflammatory response in the lungs of mice after poxvirus infection, and the viral load reaches a peak on the 6th to 10th day after infection, accompanied by pathological changes such as pulmonary edema and necrosis; in addition, the model can also cause damage to the blood-brain barrier in the olfactory bulb, and lead to the activation and increase in the number of some glial neurons (including microglia and astrocytes) in the olfactory bulb, as well as a decrease in the activity or number of olfactory nerves.

[0010] In a second aspect, the present application discloses a method for constructing an animal model of mouse nerve damage based on poxvirus infection, the steps of which are as follows: after anesthetizing the mice, the mice are infected by nasal drops, and then placed in an independently ventilated isolation cage (IVC) for normal feeding.

[0011] In a third aspect, the present application discloses the application of the poxvirus-infected mouse nerve injury animal model described in the first aspect in the research and development of poxvirus-related nerve injury drugs.

[0012] Furthermore, the research and development of the poxvirus-related nerve damage drugs includes the screening and evaluation of antiviral drugs, immunomodulatory drugs, and nerve repair drugs.

[0013] In a fourth aspect, the present application discloses the application of the poxvirus-infected mouse nerve injury animal model described in the first aspect in the prevention research of diseases related to nerve injury caused by poxvirus.

[0014] Furthermore, the research on the prevention of diseases related to nerve damage caused by the poxvirus includes vaccine development, preventive drug screening and effect evaluation.

[0015] In the fifth aspect, the present application discloses the application of the poxvirus-infected mouse nerve injury animal model described in the first aspect in the study of the pathogenic mechanism of poxvirus-related nerve injury, especially the study of the damage mechanism and repair process of the virus on neural tissue (such as olfactory bulb, etc.).

[0016] In summary, the present invention takes poxvirus VR-1354 infection of C57BL / 6N mice as an example to construct a new animal model of poxvirus-induced nerve damage through respiratory infection. C57BL / 6N mice were infected with poxvirus VR-1354 by nasal drip, the weight of mice was recorded for 14 consecutive days, and the lungs of mice were sampled on the 3rd, 7th and 14th days, and the mice were stained with Evans blue. The experimental results showed that on the 3rd day after infection, the lungs of mice began to have an inflammatory reaction, and a large amount of viral DNA could be detected. In the 7-day test, the peak of the virus could be found in the lungs, and obvious edema, necrosis, etc. appeared. On the 14th day, the viral load dropped, and the exudation in the lungs began to be absorbed, and a large number of mixed inflammatory cells appeared. Evans blue staining also proved that the virus infection can cause certain damage to the blood-brain barrier of the olfactory bulb. Through the fluorescent staining of microglia and astrocytes in the olfactory bulb, it was found that microglia showed obvious increase and activation phenomenon and astrocytes increased significantly. The activity or number of olfactory nerves showed a decreasing trend after infection and gradually recovered. Therefore, the vaccinia virus VR-1354 used in the present invention can cause severe infection in C57BL / 6N mice, cause certain damage to the blood-brain barrier of the olfactory bulb, and cause activation and increase of glial nerve cells in the olfactory bulb and decrease in the number or activity of olfactory nerves. In view of the high conservatism of poxvirus, this method has significant application value for establishing a model of poxvirus-infected nerve damage (encephalopathy) and related disease prevention and treatment and related pharmaceutical fields. For example, the model constructed by this method can be used for candidate therapeutic or preventive drugs (antiviral drugs, immunomodulatory drugs, nerve repair drugs, etc.) for poxvirus-infected olfactory nerve damage, vaccine research and development and effectiveness screening and evaluation. The model constructed by this method will help accelerate the discovery and optimization of new therapies and enhance the ability to prevent future poxvirus-infected related nerve damage diseases (encephalopathy). BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 : Change curve of mouse body weight under different challenge concentrations;

[0018] Figure 2 :The body weight change curve of C57BL / 6N mice 14 days after VR-1354 virus infection;

[0019] Figure 3 :Survival curve of C57BL / 6N mice 14 days after VR-1354 virus infection;

[0020] Figure 4 :Photos of lung lesions in C57BL / 6N mice after VR-1354 infection;

[0021] Figure 5 :LD 50Changes in the lungs at different days after infection with the virus of different concentrations;

[0022] Figure 6 :LD 50 Changes in lung viral load after viral infection;

[0023] Figure 7 :LD 50 Changes in viral load in mouse brain after infection with high concentrations of virus;

[0024] Figure 8 :LD 50 Changes in viral load in different brain tissues of mice after infection with different concentrations of virus (A: nasal mucosal viral load; B: olfactory bulb viral load; C: brain viral load; D: cerebellum viral load);

[0025] Fig. 9 :LD 50 Evans blue staining images at different days after infection with different concentrations of virus;

[0026] Fig.10 :Microglia staining (20x) and quantitative statistical analysis;

[0027] Fig.11 :Microglial morphological changes and cell body size and synapse number statistics;

[0028] Fig.12 : Astrocyte staining and fluorescence intensity analysis;

[0029] Fig.13 : Olfactory nerve staining and fluorescence intensity analysis. DETAILED DESCRIPTION

[0030] The technical scheme and effects of the present application are further described in detail below in conjunction with the examples. It is to be understood that the specific embodiments described herein are only used to explain the invention, rather than to limit the invention. It should also be noted that the present invention uses the poxvirus VR-1354 as an example to carry out relevant experiments. The virulence of VR-1354 is between the common monkeypox virus and VTT, that is, it has strong infection and pathogenicity, and can be operated in a biosafety level 2 laboratory, which can ensure the relative safety of the experimenters. To further disclose the experimental process, the following is an example of the implementation method in C57BL / 6N mice.

[0031] The meaning of all technical terms and scientific terms used herein is intended to be the same as those generally understood by those skilled in the art, including those changes in technology that are obvious to those skilled in the art or replacement of equivalent technology. As used herein, the terms "include", "comprise", "comprising", "having", "containing" or "involving" and other variant forms thereof in this article are inclusive or open, and do not exclude other unlisted elements or method steps.

[0032] Example

[0033] 1. Vaccinia virus VR-1354 virus amplification:

[0034] Inoculate the revived Vero cells into a T25 cell flask, add 10 mL of 10% serum DMEM medium, and culture in a 37°C incubator for two days. Resuspend the digested cells with 10 mL of 10% serum DMEM, take 10 μL of the cell suspension, dilute it 10 times, and count it using a cell counting plate. 5 Cells were inoculated, and 10% serum DMEM was added to the d10 culture dish to a total volume of 10 mL. The dish was placed in a 37°C incubator for two days. The cell culture medium was discarded, 2% serum DMEM was added to 10 mL, the virus was inoculated, and the dish was placed in a 37°C incubator for two days. A portion of the culture medium was discarded, the adherent cells were scraped off, and transferred to a 15 mL centrifuge tube and stored in a -80°C refrigerator.

[0035] 2. Vaccinia virus VR-1354 virus purification:

[0036] (1) The collected cell culture fluid was repeatedly frozen and thawed three times.

[0037] (2) Centrifuge the culture medium after freeze-thaw at 1200 rpm / min for 15 min, collect the supernatant and discard the precipitate.

[0038] (3) Centrifuge at 30,000 rpm / min, 80 min, and 4°C using an ultracentrifuge, discard the supernatant, collect the precipitate, resuspend the virus in 500 μL PBS, dissolve overnight, and store the resulting virus suspension in a -80°C refrigerator.

[0039] 4. Poxvirus VR-1354 plaque assay:

[0040] (1) Vero cells were plated into 6-well plates and cultured in a 37°C cell culture incubator until the cells grew confluently to form a monolayer.

[0041] (2) The sample to be tested was diluted 10 times in a series using 2% FBSDMEM medium.

[0042] (3) The culture medium in the 6-well plate was discarded, and 1000 μL of the gradient diluted sample to be tested was added to each well and adsorbed at 37°C for 90 min.

[0043] (4) After adsorption, each well was washed three times with DMEM containing 1% FBS to wash away the unadsorbed virus, and finally 500 μL of DMEM culture medium containing 3% FBS, 1% double antibody, and 1% agarose was added.

[0044] (5) After the added agar DMEM medium solidifies, place the well plate in a 37°C cell culture incubator for 60 hours until obvious plaques are formed. Add 250 μL of 0.5% crystal violet staining solution to each well and stain overnight at room temperature.

[0045] (6) Wash off the agar DMEM medium, count the number of plaques formed in the well plate, and calculate the virus titer based on the corresponding sample dilution multiple.

[0046] 5. LD of VR-1354 poxvirus-infected mice 50 Determination:

[0047] 48 female C57BL / 6N mice were selected and divided into one control group and five experimental groups. The control group had 8 mice and each experimental group had 8 mice. The mice were anesthetized with isoflurane and then infected by intranasal drops. The mice in the control group were infected by intranasal drops with 40 μL PBS. Each experimental group was infected with 5×10 6 PFU, 5×10 5 PFU, 5×10 4 PFU, 5×10 3 PFU, 5×10 2 PFU of virus

[0048] Three days before the experiment, the mice raised in the SPF area were transferred to the secondary laboratory, marked according to the group, and then placed in an independent ventilation isolation cage (IVC) for normal feeding. Before the experiment, the virus stock solution was prepared according to the experimental concentration, and the whole operation was carried out on ice and kept on ice for standby. The mice that had completed the virus attack were placed in the IVC for feeding.

[0049] 6. Observe the changes in mouse body weight and survival rate:

[0050] For mice that have completed the infection, observe and record their weight and the number of survivors every day for 14 consecutive days, keep records, and draw a weight curve.

[0051] 7. LD of VR-1354 virus in C57BL / 6N mice 50 Inspection:

[0052] Practical calculation of double LD 50C57BL / 6N mice were infected with VR-1354 virus of different concentrations and challenged by intranasal drops. The weight changes and survival of mice were recorded for 14 consecutive days after challenge.

[0053] 8. Remove mouse lungs:

[0054] (1) On the 3rd, 7th, and 14th days after mice were infected with the virus, three mice from each group were killed and their chest cavities were opened.

[0055] (2) The left and right lungs of the mouse were completely removed, the largest lung lobe of the mouse was separated, and fixed in paraformaldehyde. The remaining lungs were quickly frozen in liquid nitrogen and stored in a -80°C refrigerator.

[0056] 9. Lung viral load detection:

[0057] Part of the lung tissue was taken, and the total DNA of the lung tissue was extracted according to the steps of the viral DNA extraction kit. Fluorescence quantitative PCR was designed to detect the content of viral DNA in the lung tissue.

[0058] name Sequence (164 bp) q-PCR F 5'GCTAAAAGCGACGTCTTGTATT 3' q-PCR 5'GTGTCATTTGTAGTTGATGTCA3'

[0059] 10. HE staining analysis of mouse lungs:

[0060] The paraformaldehyde-fixed mouse lungs were prepared into paraffin sections and stained with HE to obtain pathological sections of the mouse lungs.

[0061] 11. Detection of virus content in mouse brain:

[0062] On the 3rd, 7th and 14th days, three brains from each group of mice were taken and divided into left and right halves. One half of the brain was fixed in paraformaldehyde and the other half was stored in a -80°C refrigerator. The tissues in the -80°C refrigerator were taken out and homogenized, and brain DNA was extracted according to the steps of the viral DNA extraction kit, and q-PCR was used to detect viral DNA in the brain.

[0063] 12. Virus load detection in various parts of mouse brain:

[0064] Fresh brain tissues were obtained from the control group and mice 3, 7, and 14 days after virus infection, and divided into three parts: olfactory bulb, cerebrum, and cerebellum using a scalpel. Fresh mouse nasal mucosa was also obtained, and brain tissue DNA was extracted according to the instructions of the viral DNA extraction kit. q-PCR was performed to detect changes in viral load in each part.

[0065] 13. Evans blue staining of mouse brain:

[0066] (1) Three mice were selected from each control group and experimental group on days 3, 7, and 14 after virus infection. The mice were injected with 2% Evans blue dye at a dose of 2 μL / g through the tail vein. Wait for 30 minutes after injection.

[0067] (2) Mice were anesthetized by intraperitoneal injection of 150 μL 1× Avertin.

[0068] (3) The mouse chest cavity was opened and the mouse was perfused by heart. PBS was used for perfusion first. After the outflowing liquid became clear, 4% paraformaldehyde tissue fixative was used for perfusion until the mouse became rigid.

[0069] (4) The mouse was dislocated by neck, the skull was opened, the brain tissue was completely removed, and stored in paraformaldehyde.

[0070] 14. Staining of microglia, astrocytes and olfactory nerves in the mouse olfactory bulb:

[0071] (1) Infect C57BL / 6N mice with a median lethal dose of virus, three mice per group

[0072] (2) The brains of mice in the control group and on days 3, 7, and 14 after infection were collected after cardiac perfusion.

[0073] (3) The brain was frozen and sliced ​​into sagittal sections with a thickness of 15-20 μm.

[0074] (4) Iba-1 was used to stain microglia, GFAP was used to stain astrocytes, and OMP was used to stain olfactory nerves.

[0075] (5) After staining, random images of the olfactory bulb were taken under a confocal microscope.

[0076] Experimental Results

[0077] 1. LD of poxvirus VR-1354 50 Measurement results:

[0078] After infecting C57BL / 6N mice with viruses diluted in geometric series, mice infected with high concentrations of the virus died quickly ( Figure 1 ), with the decrease of the amount of infected virus, the survival of mice increased significantly (Table 1), and the LD was calculated according to the modified Koch method. 50 , LD of vaccinia virus VR-1354 in C57BL / 6N mice 50 2.5×10 3 PFU.

[0079] Table 1 Survival of mice at 14 days

[0080]

[0081] 2. Mouse weight curve:

[0082] The mice were challenged with the drug according to the median lethal dose, and the weight curve of the mice was recorded for 14 days.

[0083] The weight of mice in the control group gradually increased after nasal drops of PBS and then stabilized. Compared with the control group, the weight of mice in the experimental group increased after nasal drops of LD 50 After the virus attack, the mice showed a significant decrease in weight, and the lowest weight was reached on the seventh day, with an average weight loss of more than 20%. From the eighth day, the weight of the mice began to maintain and gradually recover ( Figure 2 By the seventh day, about half of the mice had lost more than 25% of their body weight and were considered ethically dead and euthanized. Figure 3 ).

[0084] The weight changes of mice after virus infection indicated that the mice had more serious symptoms of the disease, and after infection, the mice showed symptoms such as fever, ruffled hair, weight loss, and decreased vitality. The weight change curve of the VR-1354 virus-infected C57BL / 6N mouse model was in line with the expected effect.

[0085] 3. Lung lesions in mice after infection with different concentrations of VR-1354 virus:

[0086] C57BL / 6N mice were infected with different concentrations of VR-1354 virus, and the lungs of the mice were taken for paraffin sections and HE staining.

[0087] The alveolar tissue of the mice in the control group was intact and clear. After infection with the VR-1354 virus, the cavity was filled with a large number of lymphocytes (indicated by the red arrow), and symptoms of inflammatory cell infiltration appeared. As the infection dose increased, the pathological phenomenon became more serious, the infiltration of inflammatory cells increased, and symptoms of cell necrosis appeared around the trachea (green arrow), accompanied by a large amount of fibrous infiltration and homogeneous red staining (blue arrow). Therefore, VR-1354 virus infection can induce lung-related lesions in mice and some symptoms of lung inflammation ( Figure 4 ).

[0088] 4. C57BL / 6N mice using LD 50 Pulmonary lesions at different times after infection with VR-1354 virus of different concentrations:

[0089] On the third day after infection, no obvious signs of pathological changes were found in the lungs of mice. Only a small amount of cell necrosis and a small amount of inflammatory cell infiltration appeared around some tracheas, and loose edema bands appeared around blood vessels (indicated by yellow arrows). On the seventh day after infection, a large amount of exudation appeared in the alveoli (indicated by black arrows), fibrous exudation appeared around the trachea (indicated by red arrows), and a large number of necrotic cells and inflammatory foci appeared (indicated by green arrows). On the fourteenth day after infection, necrosis and post-necrotic bronchi and mixed inflammatory cell infiltration foci around blood vessels and trachea developed (indicated by brown arrows). And some exudates began to be absorbed (indicated by blue arrows) ( Figure 5 ).

[0090] 5. Detection of viral load in mouse lungs:

[0091] Using LD 50 The lungs of mice infected with VR-1354 poxvirus were homogenized on the 3rd, 7th and 14th days after infection, and q-PCR quantitative detection was performed, using viral DNA with known viral load as the standard curve. The lung viral load was calculated. After C57BL / 6N mice were infected with VR-1354 virus, a large amount of viral replication was detected in the lungs on the third day, and a higher viral load was detected on the seventh day. On the 14th day, the virus began to decrease significantly, indicating that after C57BL / 6N mice were infected with the virus, the immune system was rapidly activated and the virus was effectively cleared ( Figure 6 ).

[0092] 6. Brain viral load detection

[0093] After C57BL / 6N mice were infected with the virus, the virus could be detected in the brain on the third day, and the virus began to multiply greatly from the third day. The virus could be detected in large quantities on the seventh day, and then gradually declined, and was basically cleared on the 14th day ( Figure 7 ).

[0094] 7. Virus load in various parts of the mouse brain and nasal mucosa:

[0095] To further explore the distribution of viruses in various parts of the mouse brain, we divided the mouse brain into the olfactory bulb, cerebrum, and cerebellum, and removed the mouse nasal mucosa to detect the viral load. After the C57BL / 6N mice were infected with the virus, the virus in the mouse nasal mucosa proliferated significantly, reaching a viral load similar to that in the lungs on the seventh day, and still contained a relatively high viral load on the fourteenth day. In the olfactory bulb of the mouse, more viral replication also occurred, but the virus was gradually cleared on the fourteenth day after infection. The presence of the virus was also found in the mouse brain and cerebellum on the seventh day, but the viral load in the brain and cerebellum was very low compared to the viral load in the nasal mucosa and olfactory bulb ( Figure 8 ).

[0096] 8. Analysis of Evans blue staining results after mice were infected with the virus:

[0097] Evans blue staining showed that the blood-brain barrier of the olfactory bulb of mice was severely damaged on the seventh day, with the entire olfactory bulb showing a distinct blue color. It was basically restored around the 14th day, but part of the blood-brain barrier was still damaged, with only a small amount of blue found near the ventral side of the olfactory bulb. No damage to the blood-brain barrier in the brain region was observed in mice ( Fig. 9 ).

[0098] 9. Analysis of microglia, astrocytes and olfactory nerves in the mouse olfactory bulb:

[0099] Fluorescence staining revealed that microglia were significantly activated on the 7th day ( Fig.10 ), and the number of microglia increased significantly, and did not show a significant decline until the 14th day ( Fig.11 The number of astrocytes also increased significantly on the 7th day, and slightly decreased on the 14th day ( Fig.12 ). At the same time, the fluorescence intensity of the olfactory nerve weakened on the 7th day and recovered slightly on the 14th day ( Fig.13 ).

[0100] This specific embodiment is merely an explanation of the present application and is not a limitation of the present application. After reading this specification, those skilled in the art may make modifications to the present embodiment without any creative contribution as needed, but such modifications are protected by the patent law as long as they are within the scope of the claims of the present application.

Claims

1. A mouse nerve injury animal model based on poxvirus infection, characterized in that: The model is constructed by infecting mice with poxvirus by intranasal drip, and the model can simulate the nerve damage and related pathological changes caused by poxvirus.

2. The mouse nerve injury animal model according to claim 1, characterized in that: The mice are C57BL / 6N mice aged 3-12 weeks.

3. The mouse nerve injury animal model according to claim 1, characterized in that: The poxvirus is the vaccinia virus with the catalog number VR-1354 on the ATCC official website.

4. The mouse nerve injury animal model according to claim 1, characterized in that: The model can cause a significant inflammatory response in the lungs of mice after poxvirus infection, and the viral load reaches a peak on the 6th to 10th day after infection, accompanied by pathological changes such as pulmonary edema and necrosis; in addition, the model can also cause damage to the blood-brain barrier in the olfactory bulb, and lead to the activation and increase in the number of some glial neurons (including microglia and astrocytes) in the olfactory bulb, as well as a decrease in the activity or number of olfactory nerves.

5. The method for constructing a mouse nerve injury animal model based on poxvirus infection according to any one of claims 1 to 4, characterized in that: The steps are as follows: After the mice are anesthetized, they are infected by intranasal drip and then placed in an independently ventilated isolation cage (IVC) for normal feeding.

6. Use of the poxvirus-infected mouse nerve injury animal model according to any one of claims 1 to 4 in the research and development of poxvirus-related nerve injury drugs.

7. The use according to claim 6, characterized in that: The research and development of poxvirus-related nerve damage drugs includes the screening and evaluation of antiviral drugs, immunomodulatory drugs, and nerve repair drugs.

8. Use of the poxvirus-infected mouse nerve injury animal model according to any one of claims 1 to 4 in the prevention research of diseases related to nerve injury caused by poxvirus.

9. The use according to claim 8, characterized in that: The research on the prevention of diseases related to nerve damage caused by the poxvirus includes vaccine development, preventive drug screening and effect evaluation.

10. Use of the poxvirus-infected mouse nerve injury animal model according to any one of claims 1 to 4 in the study of the pathogenesis of poxvirus-related nerve injury, especially the study of the damage mechanism and repair process of the virus on nerve tissue (such as olfactory bulb, etc.).

Citation Information

Patent Citations

  • Recombinant adeno-associated virus-hepatitis B virus 1.3 (rAAV8-HBV1.3) for establishing HBV mouse model

    CN102311974A

  • Luciferase labeling system of ectromelia virus and application of luciferase labeling system

    CN103305479A

  • Ectromelia virus GFP (green fluorescent protein) tracer system and application thereof

    CN103333866A

  • Bioactive preparation of specific anti-variola virus infection model strain and application of bioactive preparation

    CN105663166A

  • Method for labeling poxvirus particles by using fluorescence and application thereof

    CN111474339A

Cited By

  • Construction method of mouse model infected by respiratory syncytial virus

    CN121818709A